How These Biotech Stocks are Faring? -- Seattle Genetics, Sangamo Therapeutics, Vertex Pharma, and VIVUS

Monday, May 15, 2017 Genetics & Stem Cells News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, May 15, 2017 /PRNewswire/ --

On Friday, May 12, 2017, the Dow Jones Industrial

Average and the S&P 500 edged 0.11% and 0.15% lower, respectively at the closing bell, while the NASDAQ Composite stayed bullish, finishing marginally higher by 0.09%. Five out of nine sectors ended last Friday's trading session in bullish territories.
Taking into consideration last Friday's market sentiment, Stock-Callers.com assessed the following Biotechnology equities this morning: Seattle Genetics Inc. (NASDAQ: SGEN), Sangamo Therapeutics Inc. (NASDAQ: SGMO), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and VIVUS Inc. (NASDAQ: VVUS). Download the free research reports on these stocks today:

http://stock-callers.com/registration

Seattle Genetics  

Bothell, Washington headquartered Seattle Genetics Inc.'s stock rose 1.64%, finishing last Friday's trading session at $63.11. A total volume of 453,133 shares was traded. The Company's shares have gained 4.90% over the previous three months and 19.59% since the start of this year. The stock is trading above its 200-day moving average by 7.15%. Additionally, shares of Seattle Genetics, which develops and commercializes targeted therapies to treat cancer worldwide, have a Relative Strength Index (RSI) of 44.88. See our free and comprehensive research report on SGEN at:

http://stock-callers.com/registration/?symbol=SGEN

Sangamo Therapeutics  

Shares in Richmond, California headquartered Sangamo Therapeutics Inc. ended at $8.20, surging 17.14% from the last trading session. The stock recorded a trading volume of 11.44 million shares, which was above its three months average volume of 828,270 shares. The Company's shares have advanced 92.94% in the past month, 112.99% over the previous three months, and 168.85% since the start of this year. The stock is trading 82.53% and 96.97% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Sangamo Therapeutics, which focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy, have an RSI of 83.68. SGMO free research report PDF is just a click away at:

http://stock-callers.com/registration/?symbol=SGMO

Vertex Pharma  

On Friday, shares in Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc. recorded a trading volume of 986,032 shares. The stock declined 0.66%, closing the day at $114.60. The Company's shares have gained 30.01% over the previous three months and 55.56% on an YTD basis. The stock is trading 8.13% above its 50-day moving average and 25.00% above its 200-day moving average. Additionally, shares of Vertex Pharma, which discovers, develops, manufactures, and commercializes medicines for serious diseases, have an RSI of 53.34. Sign up for your complimentary report on VRTX at:

http://stock-callers.com/registration/?symbol=VRTX

VIVUS  

At the close of trading on Friday, shares in Campbell, California headquartered VIVUS Inc. recorded a trading volume of 428,801 shares. The stock finished the session flat at $1.01. The Company's shares are trading below their 50-day moving average by 4.93%. Furthermore, shares of VIVUS, which develops and commercializes therapies to address unmet medical needs in the US and the European Union, have an RSI of 42.35. Register for free on Stock-Callers.com and download the latest research report on VVUS at:

http://stock-callers.com/registration/?symbol=VVUS

--

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number:  +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook